Triple
T15478688
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | kynurenine pathway |
E376854
|
entity |
| Predicate | rateLimitingEnzyme |
P118413
|
FINISHED |
| Object |
indoleamine 2,3-dioxygenase 1
Indoleamine 2,3-dioxygenase 1 is an immune-regulatory enzyme that catalyzes the initial oxidative degradation of tryptophan along the kynurenine pathway, influencing inflammation, tolerance, and tumor immune evasion.
|
E1160708
|
NE FINISHED |
How this triple was built (5 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: indoleamine 2,3-dioxygenase 1 | Statement: [kynurenine pathway, rateLimitingEnzyme, indoleamine 2,3-dioxygenase 1]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: indoleamine 2,3-dioxygenase 1 Context triple: [kynurenine pathway, rateLimitingEnzyme, indoleamine 2,3-dioxygenase 1]
-
A.
indoleamine 2,3-dioxygenase 2
Indoleamine 2,3-dioxygenase 2 is an immune-regulatory heme-containing enzyme that catalyzes the oxidative degradation of tryptophan along the kynurenine pathway, influencing inflammation and immune tolerance.
-
B.
tryptophan 2,3-dioxygenase
Tryptophan 2,3-dioxygenase is a heme-containing enzyme that catalyzes the first and rate-limiting step in the oxidative degradation of tryptophan, playing a key role in tryptophan metabolism and regulation.
-
C.
kynurenine aminotransferase II
Kynurenine aminotransferase II is a pyridoxal phosphate-dependent enzyme that converts kynurenine to kynurenic acid, a neuroactive metabolite implicated in brain function and neurodegenerative disorders.
-
D.
kynureninase
Kynureninase is a pyridoxal phosphate-dependent enzyme that catalyzes key steps in tryptophan degradation within the kynurenine pathway, contributing to the production of NAD⁺ and other metabolites.
-
E.
aromatic L-amino acid decarboxylase
Aromatic L-amino acid decarboxylase is a pyridoxal phosphate–dependent enzyme that catalyzes the decarboxylation of aromatic L-amino acids to produce key neurotransmitters such as dopamine and serotonin.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg
Description generation
gpt-5.1
Instruction
Generate a one-sentence description of the target entity. You are given a context triple in the form (subject, predicate, object), where the object is the target entity. # Instructions Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. Avoid repeating the information from the triple, unless really essential. # Response Format Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: indoleamine 2,3-dioxygenase 1 Triple: [kynurenine pathway, rateLimitingEnzyme, indoleamine 2,3-dioxygenase 1]
Generated description
Indoleamine 2,3-dioxygenase 1 is an immune-regulatory enzyme that catalyzes the initial oxidative degradation of tryptophan along the kynurenine pathway, influencing inflammation, tolerance, and tumor immune evasion.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: indoleamine 2,3-dioxygenase 1 Target entity description: Indoleamine 2,3-dioxygenase 1 is an immune-regulatory enzyme that catalyzes the initial oxidative degradation of tryptophan along the kynurenine pathway, influencing inflammation, tolerance, and tumor immune evasion.
-
A.
indoleamine 2,3-dioxygenase 2
Indoleamine 2,3-dioxygenase 2 is an immune-regulatory heme-containing enzyme that catalyzes the oxidative degradation of tryptophan along the kynurenine pathway, influencing inflammation and immune tolerance.
-
B.
tryptophan 2,3-dioxygenase
Tryptophan 2,3-dioxygenase is a heme-containing enzyme that catalyzes the first and rate-limiting step in the oxidative degradation of tryptophan, playing a key role in tryptophan metabolism and regulation.
-
C.
kynurenine aminotransferase II
Kynurenine aminotransferase II is a pyridoxal phosphate-dependent enzyme that converts kynurenine to kynurenic acid, a neuroactive metabolite implicated in brain function and neurodegenerative disorders.
-
D.
kynureninase
Kynureninase is a pyridoxal phosphate-dependent enzyme that catalyzes key steps in tryptophan degradation within the kynurenine pathway, contributing to the production of NAD⁺ and other metabolites.
-
E.
aromatic L-amino acid decarboxylase
Aromatic L-amino acid decarboxylase is a pyridoxal phosphate–dependent enzyme that catalyzes the decarboxylation of aromatic L-amino acids to produce key neurotransmitters such as dopamine and serotonin.
- F. None of above. chosen
PD
Predicate disambiguation
gpt-5-mini-2025-08-07
Target predicate: rateLimitingEnzyme Context triple: [kynurenine pathway, rateLimitingEnzyme, indoleamine 2,3-dioxygenase 1]
-
A.
enzymeType
Indicates the specific class or category of enzyme associated with an entity or reaction.
-
B.
supportsRateLimiting
Indicates that one entity provides or is compatible with mechanisms to restrict the rate at which another entity can perform actions or process requests.
-
C.
aimedToLimit
Indicates an action or policy that was intentionally directed toward restricting, reducing, or constraining something.
-
D.
enzymeSystem
Indicates a relationship where an entity functions as, or is part of, a specific enzyme system involved in catalyzing biochemical reactions.
-
E.
isMetabolizedBy
Indicates that a substance is biochemically broken down or transformed through metabolic processes carried out by a specified organism, cell type, or enzyme system.
- F. None of above. chosen
Provenance (7 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d85cd21dcc81908646251b1c26ea00 |
completed | April 10, 2026, 2:13 a.m. |
| NER | Named-entity recognition | batch_69e03f8a77a081909f12f13660452f4a |
completed | April 16, 2026, 1:46 a.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69ff36595bfc8190a0d60b3cb875ccc5 |
completed | May 9, 2026, 1:27 p.m. |
| NEDg | Description generation | batch_69ff376dac388190ab3b7e3553d2de29 |
completed | May 9, 2026, 1:32 p.m. |
| NED2 | Entity disambiguation (via description) | batch_69ff382f1bbc8190810d0d825430f9ea |
completed | May 9, 2026, 1:35 p.m. |
| PD | Predicate disambiguation | batch_69ded2874b788190999158e0f043be21 |
completed | April 14, 2026, 11:49 p.m. |
| PDg | Predicate description generation | batch_69ded5deee00819099fa3e43313312e1 |
completed | April 15, 2026, 12:03 a.m. |
Created at: April 10, 2026, 3:34 a.m.